These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies. Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699 [TBL] [Abstract][Full Text] [Related]
10. Impact of conventional lipid-lowering therapy on circulating levels of PCSK9: protocol for a systematic review and meta-analysis of randomised controlled trials. Luo J; Huang T; Xu R; Wang X; Yang Y; Li L; Zhang X; Zhang Y; Yang R; Wang J; Yang H; Ma Y; Yang B; Wang T; Jiao L BMJ Open; 2022 Sep; 12(9):e061884. PubMed ID: 36691198 [TBL] [Abstract][Full Text] [Related]
12. Reduction of C-reactive protein, low-density lipoprotein cholesterol, and its relationship with cardiovascular events of different lipid-lowering therapies: A systematic review and meta-analysis of randomized controlled trials. Yang W; Cai X; Lin C; Lv F; Zhu X; Han X; Ji L Medicine (Baltimore); 2022 Sep; 101(37):e30563. PubMed ID: 36123891 [TBL] [Abstract][Full Text] [Related]
13. PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis. Khan SU; Yedlapati SH; Lone AN; Hao Q; Guyatt G; Delvaux N; Bekkering GET; Vandvik PO; Riaz IB; Li S; Aertgeerts B; Rodondi N BMJ; 2022 May; 377():e069116. PubMed ID: 35508321 [TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia: A frequentist network meta-analysis. Zhao Z; Du S; Shen S; Luo P; Ding S; Wang G; Wang L Medicine (Baltimore); 2019 Feb; 98(6):e14400. PubMed ID: 30732185 [TBL] [Abstract][Full Text] [Related]
15. Three Musketeers for Lowering Cholesterol: Statins, Ezetimibe and Evolocumab. Xu Q; Deng Y; Xiao J; Liu X; Zhou M; Ren Z; Peng J; Tang Y; Jiang Z; Tang Z; Liu L Curr Med Chem; 2021; 28(5):1025-1041. PubMed ID: 32368969 [TBL] [Abstract][Full Text] [Related]
16. 2017 Taiwan lipid guidelines for high risk patients. Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI; J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176 [TBL] [Abstract][Full Text] [Related]
17. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons. Yadav K; Sharma M; Ferdinand KC Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986 [TBL] [Abstract][Full Text] [Related]
18. Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention. Michaeli DT; Michaeli JC; Albers S; Boch T; Michaeli T Am J Cardiovasc Drugs; 2023 Sep; 23(5):477-495. PubMed ID: 37486464 [TBL] [Abstract][Full Text] [Related]
19. [Modern lipid-lowering drugs-A means to counter the problem of undertreatment?]. Katzmann JL; Laufs U Inn Med (Heidelb); 2022 Dec; 63(12):1316-1322. PubMed ID: 35391570 [TBL] [Abstract][Full Text] [Related]
20. The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function. Di Costanzo A; Indolfi C; Sorrentino S; Esposito G; Spaccarotella CAM Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511498 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]